160 related articles for article (PubMed ID: 38641241)
21. Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma.
Okita Y; Kano-Fujiwara R; Nakatsuka SI; Honma K; Kinoshita M
Exp Hematol Oncol; 2021 Apr; 10(1):29. PubMed ID: 33902692
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials.
Wang J; Zhou H; Mu M; Zhao A; Cai Z; Li L; Wang M; Niu T
Front Immunol; 2022; 13():1034253. PubMed ID: 36439091
[TBL] [Abstract][Full Text] [Related]
23. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
Song Y; Zhou K; Zou D; Zhou J; Hu J; Yang H; Zhang H; Ji J; Xu W; Jin J; Lv F; Feng R; Gao S; Guo H; Zhou L; Elstrom R; Huang J; Novotny W; Wei R; Zhu J
Clin Cancer Res; 2020 Aug; 26(16):4216-4224. PubMed ID: 32461234
[TBL] [Abstract][Full Text] [Related]
24. Sustained response following BTK inhibitors based treatment in HIV-related primary central nervous system lymphoma: case report.
Zhou Y; Wang X; Lin X; Wang J; Yan X; Wen Y
AIDS Res Ther; 2023 Aug; 20(1):63. PubMed ID: 37644480
[TBL] [Abstract][Full Text] [Related]
25. The role of additional radiotherapy for primary central nervous system lymphoma.
Zacher J; Kasenda B; Engert A; Skoetz N
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009211. PubMed ID: 24931518
[TBL] [Abstract][Full Text] [Related]
26. Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.
Paillassa J; Safa F; Troussard X
Ther Adv Hematol; 2022; 13():20406207221090886. PubMed ID: 35450208
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of first-line combination therapy versus monotherapy for vitreoretinal lymphoma: a systematic review and meta-analysis.
Gao J; Peng X; Wang L
BMC Ophthalmol; 2023 Nov; 23(1):477. PubMed ID: 37993841
[TBL] [Abstract][Full Text] [Related]
28. High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis.
Li Y; Li Y; Zeng R; He Y; Liang L; Ou L; Su C; Zhou H; Xiao L
J Cancer; 2023; 14(17):3182-3190. PubMed ID: 37928429
[No Abstract] [Full Text] [Related]
29. Clinical characteristics and prognosis of patients with newly diagnosed primary central nervous system lymphoma: a multicentre retrospective analysis.
Bai SJ; He JX; Zheng YJ; Geng Y; Gao YN; Zhang CX; Wang YR; Qin LY; Wang WJ; Yang LH
Ann Hematol; 2024 May; ():. PubMed ID: 38761184
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Autologous Stem-Cell Transplantation as Part of First-Line Treatment for Newly Diagnosed Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis.
Liu J; Guo J; Sun X; Liu Y; Gao C
Front Oncol; 2021; 11():799721. PubMed ID: 35096600
[TBL] [Abstract][Full Text] [Related]
31. A novel Bruton's tyrosine kinase inhibitor JDB175 shows potent efficacy to suppress central nervous system lymphoma.
Xia Y; Li X; Jiang N; Wei X
MedComm (2020); 2023 Dec; 4(6):e424. PubMed ID: 37929016
[TBL] [Abstract][Full Text] [Related]
32. Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma.
Mei M; Tsai NC; Palmer J; Armenian S; Chen R; Rosen S; Forman S; Popplewell L; Kwak L; Martin P; Maddocks K; Bond D; Herrera AF
Clin Lymphoma Myeloma Leuk; 2024 Apr; ():. PubMed ID: 38693037
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy and Prognosis of Chemotherapy Regimen Containing BTK Inhibitor in Treatment of Recurrent/Refractory Mantle Cell Lymphoma].
Chen H; Liu XY; Chang Y; Chen ZQ; Li WQ; Zhang L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):125-131. PubMed ID: 38387910
[TBL] [Abstract][Full Text] [Related]
34. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
35. The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants.
Wang S; Zhu Y; Qian X; Ding T; Yuan Y; Li Y; Wu H; Chen T
Adv Clin Exp Med; 2023 Aug; 32(8):855-863. PubMed ID: 36881367
[TBL] [Abstract][Full Text] [Related]
36. Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
del Rio MS; Choquet S; Hoang-Xuan K; Glaisner S; Fourme E; Janvier M; Soussain C
J Neurooncol; 2011 Nov; 105(2):409-14. PubMed ID: 21656329
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of BTKis in Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis.
Zhang Y; Ye J; Chen H; Zhou D; Ji C
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473226
[TBL] [Abstract][Full Text] [Related]
38. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Mato AR; Shah NN; Jurczak W; Cheah CY; Pagel JM; Woyach JA; Fakhri B; Eyre TA; Lamanna N; Patel MR; Alencar A; Lech-Maranda E; Wierda WG; Coombs CC; Gerson JN; Ghia P; Le Gouill S; Lewis DJ; Sundaram S; Cohen JB; Flinn IW; Tam CS; Barve MA; Kuss B; Taylor J; Abdel-Wahab O; Schuster SJ; Palomba ML; Lewis KL; Roeker LE; Davids MS; Tan XN; Fenske TS; Wallin J; Tsai DE; Ku NC; Zhu E; Chen J; Yin M; Nair B; Ebata K; Marella N; Brown JR; Wang M
Lancet; 2021 Mar; 397(10277):892-901. PubMed ID: 33676628
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
Wang Z; Zhou H; Xu J; Wang J; Niu T
Front Immunol; 2022; 13():1070660. PubMed ID: 36685572
[TBL] [Abstract][Full Text] [Related]
40. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
